CN101438155B - 一种预测使用酪氨酸激酶抑制剂的处理的心脏毒性的方法 - Google Patents

一种预测使用酪氨酸激酶抑制剂的处理的心脏毒性的方法 Download PDF

Info

Publication number
CN101438155B
CN101438155B CN2007800136974A CN200780013697A CN101438155B CN 101438155 B CN101438155 B CN 101438155B CN 2007800136974 A CN2007800136974 A CN 2007800136974A CN 200780013697 A CN200780013697 A CN 200780013697A CN 101438155 B CN101438155 B CN 101438155B
Authority
CN
China
Prior art keywords
fatty acid
cell
acid oxidation
tyrosine kinase
kinase inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2007800136974A
Other languages
English (en)
Chinese (zh)
Other versions
CN101438155A (zh
Inventor
S·S·巴克斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Targeted Molecular Diagnostics LLC
Original Assignee
Targeted Molecular Diagnostics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targeted Molecular Diagnostics LLC filed Critical Targeted Molecular Diagnostics LLC
Publication of CN101438155A publication Critical patent/CN101438155A/zh
Application granted granted Critical
Publication of CN101438155B publication Critical patent/CN101438155B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5061—Muscle cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/04—Alpha- or beta- amino acids
    • C12P13/22—Tryptophan; Tyrosine; Phenylalanine; 3,4-Dihydroxyphenylalanine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G01N2333/4706—Regulators; Modulating activity stimulating, promoting or activating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
CN2007800136974A 2006-02-27 2007-02-27 一种预测使用酪氨酸激酶抑制剂的处理的心脏毒性的方法 Expired - Fee Related CN101438155B (zh)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US77709606P 2006-02-27 2006-02-27
US60/777,096 2006-02-27
US82123006P 2006-08-02 2006-08-02
US60/821,230 2006-08-02
US82737206P 2006-09-28 2006-09-28
US60/827,372 2006-09-28
US82834506P 2006-10-05 2006-10-05
US60/828,345 2006-10-05
US86773606P 2006-11-29 2006-11-29
US60/867,736 2006-11-29
PCT/US2007/062871 WO2007101191A2 (en) 2006-02-27 2007-02-27 Compositions and methods for reducing cellular fat and for predicting cardiac toxicity and upon treatment with tyrosine kinase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN2013101368247A Division CN103217520A (zh) 2006-02-27 2007-02-27 用于减少细胞脂肪和预测用酪氨酸激酶抑制剂治疗后的心脏毒性的组合物和方法

Publications (2)

Publication Number Publication Date
CN101438155A CN101438155A (zh) 2009-05-20
CN101438155B true CN101438155B (zh) 2013-04-24

Family

ID=38459790

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2007800136974A Expired - Fee Related CN101438155B (zh) 2006-02-27 2007-02-27 一种预测使用酪氨酸激酶抑制剂的处理的心脏毒性的方法
CN2013101368247A Pending CN103217520A (zh) 2006-02-27 2007-02-27 用于减少细胞脂肪和预测用酪氨酸激酶抑制剂治疗后的心脏毒性的组合物和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2013101368247A Pending CN103217520A (zh) 2006-02-27 2007-02-27 用于减少细胞脂肪和预测用酪氨酸激酶抑制剂治疗后的心脏毒性的组合物和方法

Country Status (11)

Country Link
US (2) US8709738B2 (https=)
EP (1) EP1996939B1 (https=)
JP (2) JP5539653B2 (https=)
KR (1) KR101390625B1 (https=)
CN (2) CN101438155B (https=)
AU (1) AU2007220094B2 (https=)
CA (1) CA2643846A1 (https=)
ES (1) ES2475162T3 (https=)
IL (1) IL193715A (https=)
NZ (2) NZ594178A (https=)
WO (1) WO2007101191A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010036910A1 (en) * 2008-09-26 2010-04-01 Yoshikazu Ohta Heart protection by administering an amp-activated protein kinase activator
WO2015027171A1 (en) * 2013-08-23 2015-02-26 Quintiles Transnational Corporation Methods for predicting toxicity in response to treatment with a drug by assessing activation of the sterol regulatory binding protein (srebp) pathway
EP3739041A1 (en) 2014-03-27 2020-11-18 The Salk Institute for Biological Studies Compositions and methods for treating type 1 and type 2 diabetes and related disorders
AU2016225076B2 (en) 2015-02-27 2018-09-13 Salk Institute For Biological Studies Reprogramming progenitor compositions and methods of use therefore
AU2017269364B2 (en) 2016-05-25 2023-08-31 Salk Institute For Biological Studies Compositions and methods for organoid generation and disease modeling
JP7032723B2 (ja) * 2017-07-21 2022-03-09 公立大学法人福島県立医科大学 薬剤の心毒性評価方法及びそのための試薬又はキット
WO2019084395A1 (en) * 2017-10-27 2019-05-02 University Of Virginia Patent Foundation COMPOUNDS AND METHODS FOR REGULATING, LIMITING OR INHIBITING AVIL EXPRESSION
TWI711458B (zh) * 2019-07-08 2020-12-01 大江生醫股份有限公司 植物發酵物及其製備方法與用於胃臟保健的用途
KR102493664B1 (ko) 2020-01-29 2023-02-01 한국화학연구원 심장 독성 예측 모델링 시스템 및 모델링 방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1436174A (zh) * 2000-06-15 2003-08-13 布里斯托尔-迈尔斯斯奎布公司 HMG－CoA还原酶抑制剂及其作为治疗与胆固醇相关疾病的药物的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9618420D0 (en) * 1996-09-04 1996-10-16 Scotia Holdings Plc Fatty acid treatment
DE19932555A1 (de) * 1999-07-13 2001-01-18 Solvay Pharm Gmbh Arzneimittel mit protektiver Wirkung gegen oxidativ-toxische und insbesondere gegen kardiotoxische Substanzen
CA2459508A1 (en) * 2001-09-24 2003-04-03 Lipomics Technologies, Inc. Methods of using quantitative lipid metabolome data
JP4611025B2 (ja) * 2002-11-04 2011-01-12 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 体内のブドウ糖または脂肪酸の代謝に関する高処理量測定のための重水素化ブドウ糖または脂肪の耐性試験
EP1980629A3 (en) 2003-08-28 2008-12-17 Ipsogen Identification of an erbb2 gene expression signature in breast cancers

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1436174A (zh) * 2000-06-15 2003-08-13 布里斯托尔-迈尔斯斯奎布公司 HMG－CoA还原酶抑制剂及其作为治疗与胆固醇相关疾病的药物的应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Tokarska-schlattner et al..Acute toxicity of doxorubicin on isolated perfused heart: response of kinases regulating energy supply..《Am. J. Physiol. Heart Circ. Physiol.》.2005,第289卷H37-H47. *

Also Published As

Publication number Publication date
KR20090008194A (ko) 2009-01-21
CN103217520A (zh) 2013-07-24
EP1996939A2 (en) 2008-12-03
NZ594178A (en) 2013-02-22
AU2007220094B2 (en) 2013-12-05
EP1996939A4 (en) 2009-07-15
JP5539653B2 (ja) 2014-07-02
IL193715A (en) 2014-06-30
KR101390625B1 (ko) 2014-04-29
WO2007101191A2 (en) 2007-09-07
NZ571465A (en) 2011-09-30
CN101438155A (zh) 2009-05-20
EP1996939B1 (en) 2014-03-26
WO2007101191A3 (en) 2007-12-13
JP2009533017A (ja) 2009-09-17
CA2643846A1 (en) 2007-09-07
ES2475162T3 (es) 2014-07-10
US20090186910A1 (en) 2009-07-23
JP2013063090A (ja) 2013-04-11
US20130288285A1 (en) 2013-10-31
US8709738B2 (en) 2014-04-29
AU2007220094A1 (en) 2007-09-07
IL193715A0 (en) 2009-05-04

Similar Documents

Publication Publication Date Title
CN101438155B (zh) 一种预测使用酪氨酸激酶抑制剂的处理的心脏毒性的方法
Thorburn et al. HRas-dependent pathways can activate morphological and genetic markers of cardiac muscle cell hypertrophy.
Thome et al. cAMP response element-mediated gene transcription is upregulated by chronic antidepressant treatment
Cartoni et al. Mitofusins 1/2 and ERRα expression are increased in human skeletal muscle after physical exercise
Harris et al. Transcriptional regulation of the thyrotropin-releasing hormone gene by leptin and melanocortin signaling
Goodman et al. Novel insights into the regulation of skeletal muscle protein synthesis as revealed by a new nonradioactive in vivo technique
Um et al. Absence of S6K1 protects against age-and diet-induced obesity while enhancing insulin sensitivity
Li et al. Transcriptional induction of MKP-1 in response to stress is associated with histone H3 phosphorylation-acetylation
Fry et al. Area postrema neurons are modulated by the adipocyte hormone adiponectin
Akeno et al. Induction of vascular endothelial growth factor by IGF-I in osteoblast-like cells is mediated by the PI3K signaling pathway through the hypoxia-inducible factor-2α
Teshigawara et al. Role of Krüppel-like factor 15 in PEPCK gene expression in the liver
Papaiahgari et al. EGFR-activated signaling and actin remodeling regulate cyclic stretch–induced NRF2-ARE activation
Ignatenko et al. Suppression of polyamine catabolism by activated Ki‐ras in human colon cancer cells
Yamaguchi et al. Activating Transcription factor 3 and early growth response 1 are the novel targets of LY294002 in a phosphatidylinositol 3-kinase–independent pathway
Clements et al. PREX1 drives spontaneous bone dissemination of ER+ breast cancer cells
WO2008016730A2 (en) Compositions and methods for reducing cellular fat
Muñoz et al. The transcription factor MEF2C mediates cardiomyocyte hypertrophy induced by IGF-1 signaling
Lee et al. Hypoxia-induced bFGF gene expression is mediated through the JNK signal transduction pathway
Tchevkina et al. The small G-protein RalA stimulates metastasis of transformed cells
Tai et al. Novel role and mechanism of protein inhibitor of activated STAT1 in spatial learning
Liu et al. Aspp2 negatively regulates body growth but not developmental timing by modulating IRS signaling in zebrafish embryos
Grove et al. Both protein activation and gene expression are involved in early vascular tube formation in vitro
Wang et al. Overexpression of G-protein-coupled receptors 65 in glioblastoma predicts poor patient prognosis
RU2570626C2 (ru) Биологический способ анализа для контроля качества нутрицевтиков и лекарственных средств
Huang et al. Retinoic acid decreases ATF-2 phosphorylation and sensitizes melanoma cells to taxol-mediated growth inhibition

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130424

Termination date: 20160227